Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Locations: - Children's Hospital of Alabama — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
- Providence Alaska Medical Center — Anchorage, Alaska
+ 391 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Baldwin Park — Baldwin Park, California
+ 207 more sites in the U.S.
Phase 3 Recruiting Industry
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …
Sponsor: AstraZeneca
NCT ID: NCT06549595
Locations: - Research Site — Huntsville, Alabama
- Research Site — Anchorage, Alaska
- Research Site — Phoenix, Arizona
+ 56 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Locations: - USA Mitchell Cancer Institute ( Site 0014) — Mobile, Alabama
- Banner MD Anderson Cancer Center ( Site 0059) — Gilbert, Arizona
- Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051) — Phoenix, Arizona
+ 43 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Locations: - City of Hope Cancer Center — Duarte, California
- University of California San Diego Medical Center — La Jolla, California
- University of California Los Angeles — Los Angeles, California
+ 29 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Locations: - Alta Bates Summit Medical Center — Berkeley, California
- City of Hope Cancer Center — Duarte, California
- Valkyrie Clinical Trials — Los Angeles, California
+ 21 more sites in the U.S.
Phase 3 Recruiting Industry
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be m…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06091254
Locations: - University of Arizona Cancer Center — Tucson, Arizona
- David Geffen School of Medicine at UCLA — Los Angeles, California
- UC Irvine Health — Orange, California
+ 17 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Locations: - Highlands Oncology Group ( Site 5405) — Springdale, Arkansas
- MemorialCare Health System - Long Beach Medical Center ( Site 5421) — Long Beach, California
- Memorial Hospital West ( Site 5410) — Pembroke Pines, Florida
+ 13 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy. The primar…
Sponsor: Kite, A Gilead Company
NCT ID: NCT07479797
Locations: - City of Hope Arizona — Goodyear, Arizona
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
- Stanford University — Stanford, California
+ 11 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who h…
Sponsor: Newave Pharmaceutical Inc
NCT ID: NCT07342478
Locations: - Orchard Healthcare Research — Skokie, Illinois
- The Center for Cancer and Blood Disorders-Bethesda — Bethesda, Maryland
- Optum Medical Group (Rhodes) P.C. — Las Vegas, Nevada
+ 3 more sites in the U.S.
Phase 3 Recruiting Industry
The main goal of this study is to show that people with certain immune problems (from Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma) get fewer serious infections when they receive Gamunex C through an IV once ever…
Sponsor: Grifols Biologicals, LLC
NCT ID: NCT07582432
Locations: - Study Site 102 — St. Petersburg, Florida
- Study Site 101 — Fort Wayne, Indiana
- Study Site 105 — Westbrook, Maine
+ 2 more sites in the U.S.
Phase 3 Recruiting Academic/Other
The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive ti…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07223021
Locations: - Memorial Sloan Kettering Cancer Center — New York, New York
- Cincinnati Children's Hospital Medical Center (Data Collection Only) — Cincinnati, Ohio
- Children's Hospital of Philadelphia (Data Collection Only) — Philadelphia, Pennsylvania
+ 2 more sites in the U.S.